We have always been on a mission to leverage our science to positively impact the lives of people living with cancer. To better reflect our innovative Tumor-Specific Immuno-Gene (T-SIGn®) viral vector approach to targeting solid tumors, PsiOxus Therapeutics has changed its name to Akamis Bio.
Our new name does not alter our mission or steadfast commitment to improving outcomes for our patients. Instead, the name change signifies our continued pursuit of innovative approaches to harness the power of the immune system to turn the tide in the battle against solid tumors – from the inside.
“Akamis” is derived from the name of one of the Greek warriors (Akamas) who was hidden inside of the Trojan Horse and who helped lead the attack on the city of Troy from within, finally turning the tide on the decade-long siege of the city. This new name is a nod to our T-SIGn® viral vector platform that turns cancer cells into “drug factories” resulting in an attack on a solid tumor from within.
The Greek word “akamas” also means “unwearying”, which accurately describes our team’s dedication to identifying and developing groundbreaking treatments for people living with cancer. We are excited to start the next chapter of our corporate history as Akamis Bio!